Mark is the Head of Research for the VCCC Alliance. He leads a team of professionals to develop, initiate and implement the seven programs of work under the research portfolio within the Strategic Program Plan. Mark’s role includes team leadership, government relations, research strategy and governance, stakeholder engagement, partnership development and fostering collaboration and collective impact across the VCCC Alliance and the oncology sector more broadly.
Previously Mark was the Global Director of Prostate Cancer Biomedical Research Programs at Movember where he oversaw a $375 million research portfolio comprising over 620 projects across 21 countries. In this role, Mark had responsibility for developing and delivering the Movember Prostate Cancer Biomedical Research Program portfolio strategy.
He has led numerous global pre-clinical and clinical drug development programs within biotech and big pharma and also led diverse cross-functional teams in the not-for-profit and health services sectors across a range of therapeutic areas and held various senior management and leadership roles within these sectors. He has also worked on strategy development initiatives with multinational organisations as a management consultant.
Mark has published widely in high-impact international medical and innovation journals, is an advisor to the global digital health collaboration platform HealthXL and is on the scientific advisory board of the PIONEER consortium - the European network for excellence in big data in prostate cancer.
Mark has a BSc (Hons) from La Trobe University, a PhD in Molecular Medicine from the University of Melbourne, an Executive MBA from the RMIT Graduate School of Business and is a registered PRINCE2 Project Management Practitioner.
